BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

ImmusanT, Inc. 

One Broadway
14th Floor
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-401-2154 Fax: n/a


SEARCH JOBS




Industry
Biotechnology

Segment
Biotechnology





 Company News
ImmusanT, Inc.’s Immunotherapy For Celiac Disease, Nexvax2, Selected As One Of Informa’s Top 10 Autoimmune/Anti-Inflammatory Projects To Watch 11/19/2014 5:04:11 PM
ImmusanT, Inc. Release: New Test In Celiac Disease Provides Powerful Tool For Diagnosis And Immune Monitoring 1/6/2014 9:52:33 AM
ImmusanT, Inc. Names Ferdinand E. Massari as Chief Medical Officer 9/9/2013 6:48:00 AM
ImmusanT, Inc. Release: New Approach to Celiac Testing Identifies More Patients at Risk 8/28/2013 9:31:39 AM
ImmusanT, Inc. Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes 8/6/2013 10:12:42 AM
ImmusanT, Inc.'s Epitope-Specific Immunotherapy for Celiac Disease Informs the Potential of Vaccines Against Other Autoimmune Diseases 4/22/2013 9:47:47 AM
New Insight Into Celiac Disease, Monash University, University of Leiden, and ImmusanT, Inc. Study 10/12/2012 7:32:19 AM
ImmusanT, Inc. Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease 9/4/2012 10:57:45 AM
ImmusanT, Inc. Relocates Offices to State-of-the-Art Innovation Facility 8/16/2012 10:42:44 AM
Sanofi (France) (SAN.PA)'s Patrick Griffin Joins Celiac Start-up ImmusanT, Inc. 3/19/2012 9:56:24 AM
12